University of Chicago, 2002, MD
Dr. Till is developing new immunotherapies for lymphoma, focusing on the approach of adoptive T cell therapy with autologous T lymphocytes genetically engineered to express a chimeric antigen receptor (CAR). Dr. Till, in collaboration with Dr. Press, is planning a clinical trial in patients with lymphoma to test these cells, which will also express a “suicide” gene that allows the cells to be killed in case they cause toxicities or other problems. Dr. Till’s laboratory is also exploring the effects of co-inhibition and co-stimulation on CAR T cells.
Dr. Till’s clinical expertise is in lymphoma as well as autologous stem cell transplantation.